Study Details
Full Title
DCA10: A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias
Principal Investigator
Nishant
Shah
Protocol Number
PRO00120024
NCT ID
NCT07491172
Phase
I
Enrollment Status
Open to Enrollment